The tide is high..., page-18

Phylogica's objective with regards to their CPP platform is all about delivering a drug to a targeted tissue, a target cell within a tissue and a target location within a cell.

What does the company need to achieve in order for their delivery platform to be successful?

1. A 30-60 x increase in cargo to correct a disease process occuring within a cell.

The GalNac cargo is the example the company highlighted in the company's announcement below (refer to diagram) of targeted delivery in the liver. As I've already mentioned, the GalNac cargo was what bound to the Asialoglycoprotein receptor and as a result increased its potency and delivery into the liver cell by 30-60 fold. Have a read of this article below. This is the drug Phylogica were referring to in the asialoglycoprotein targeting space.

https://www.nature.com/articles/d41586-018-05867-7 

2. Why are the recent company's HSV results encouraging? Because the in vitro test tube performance of Phylogica's second generation CPPs included candidates capable of delivering 25-150 times as much cargo into a target cell when compared to the cargo alone.Phylogica's second generation peptides are able to deliver 25-150 times (in vitro) as much cargo into a target cell compared to a cargo alone. That's encouraging because there appears to be a direct correlation with regards to performance in a test tube and outcomes in an animal model.

Let's see if this translates into meaningful in-vivo readouts. If it does, then the game is on imv.

https://hotcopper.com.au/threads/ann-ceo-letter-and-operational-update.4606263/?post_id=37138911

Tony